Hepatitis C secondary prevention: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
Line 12: Line 12:
* Evaluation for other conditions that may accelerate liver fibrosis, including HBV and HIV infections
* Evaluation for other conditions that may accelerate liver fibrosis, including HBV and HIV infections
* Immunization against other hepatitis viruses([[hepatitis A]] and [[hepatitis B]]) is highly recommended<ref name="aasld2014">AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed July 27, 2014.</ref><br>
* Immunization against other hepatitis viruses([[hepatitis A]] and [[hepatitis B]]) is highly recommended<ref name="aasld2014">AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed July 27, 2014.</ref><br>
* Studies have demonstrated an association between [[treatment]]-induced sustained viral clearance and low extra-[[hepatic]] manifestations (such as, [[cryoglobulinemic vasculitis]], B-cell [[nonHodgkin’s lymphoma]], [[acute coronary syndrome]]<ref name="pmid25398770">{{cite journal |vauthors=Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY |title=Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection |journal=Gut |volume=64 |issue=3 |pages=495–503 |date=March 2015 |pmid=25398770 |doi=10.1136/gutjnl-2014-308163 |url=}}</ref>, [[cardiovascular]] disease<ref name="pmid25716707">{{cite journal |vauthors=Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ |title=Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes |journal=Hepatology |volume=62 |issue=2 |pages=355–64 |date=August 2015 |pmid=25716707 |doi=10.1002/hep.27766 |url=}}</ref>, [[insulin resistance]], and [[type 2 diabetes]]<ref name="pmid29703790">{{cite journal |vauthors=Cacoub P, Desbois AC, Comarmond C, Saadoun D |title=Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis |journal=Gut |volume=67 |issue=11 |pages=2025–2034 |date=November 2018 |pmid=29703790 |doi=10.1136/gutjnl-2018-316234 |url=}}</ref> risk for [[Hepatitis C]].


===Precautions to prevent transmission to other individuals include:<ref name="who">World Health Organization (WHO) 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection.http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed online on July 24,2014.</ref>===
===Precautions to prevent transmission to other individuals include:<ref name="who">World Health Organization (WHO) 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection.http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed online on July 24,2014.</ref>===

Revision as of 04:55, 1 May 2021

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C secondary prevention

CDC on Hepatitis C secondary prevention

Hepatitis C secondary prevention in the news

Blogs on Hepatitis C secondary prevention

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Patients who are diagnosed with chronic hepatitis C require vaccination against other hepatitis viruses, limiting of alcohol intake, and evaluation for other comorbid conditions in order to limit further hepatic damage. Patients should be instructed on how to avoid HCV transmission to others.

Secondary Prevention

Patients who are diagnosed with chronic hepatitis C require specific measures to limit further hepatic damage and to avoid progression to cirrhosis.

Important measures to avoid reduce the risk of further hepatic injury include:

Precautions to prevent transmission to other individuals include:[5]

  • Covering completely any cut or wound with a waterproof dressing would help in reduction of transmission of the virus
  • Ensuring that the injecting equipment is not shared
  • Avoiding blood or organ donation
  • Not sharing personal items such as toothbrushes or razors
  • Engaging in protected intercourse whenever possible

There are currently no CDC recommendations to restrict a healthcare worker who is infected with HCV. The risk of transmission from an infected healthcare worker to a patient appears to be very low.[1] All healthcare personnel, including those who are HCV positive, should follow strict aseptic technique and standard precautions, including appropriate hand hygiene, use of protective barriers, and safe injection practices.[1]

References

  1. 1.0 1.1 1.2 AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed July 27, 2014.
  2. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY (March 2015). "Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection". Gut. 64 (3): 495–503. doi:10.1136/gutjnl-2014-308163. PMID 25398770.
  3. Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ (August 2015). "Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes". Hepatology. 62 (2): 355–64. doi:10.1002/hep.27766. PMID 25716707.
  4. Cacoub P, Desbois AC, Comarmond C, Saadoun D (November 2018). "Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis". Gut. 67 (11): 2025–2034. doi:10.1136/gutjnl-2018-316234. PMID 29703790.
  5. World Health Organization (WHO) 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection.http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed online on July 24,2014.

Template:WH Template:WS

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Navigation menu